Direxion Daily S&P Biotech Bear 3X Shares (LABD)
| Assets | $72.27M |
| Expense Ratio | 1.07% |
| PE Ratio | n/a |
| Shares Out | 12.92M |
| Dividend (ttm) | $0.28 |
| Dividend Yield | 4.96% |
| Ex-Dividend Date | Jun 24, 2025 |
| Payout Frequency | Quarterly |
| Payout Ratio | n/a |
| Volume | 16,975,279 |
| Open | 5.66 |
| Previous Close | 5.74 |
| Day's Range | 5.36 - 5.75 |
| 52-Week Low | 4.78 |
| 52-Week High | 16.05 |
| Beta | -2.51 |
| Holdings | 9 |
| Inception Date | May 28, 2015 |
About LABD
Fund Home PageThe Direxion Daily S&P Biotech Bear 3X Shares (LABD) is an exchange-traded fund that is based on the S&P Biotechnology Select Industry index. The fund provides daily 3 times inverse exposure to the S&P Biotechnology Select Industry Index. LABD was launched on May 28, 2015 and is issued by Direxion.
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Jun 24, 2025 | $0.03696 | Jul 1, 2025 |
| Mar 25, 2025 | $0.05463 | Apr 1, 2025 |
| Dec 23, 2024 | $0.12639 | Dec 31, 2024 |
| Sep 24, 2024 | $0.05774 | Oct 1, 2024 |
| Jun 25, 2024 | $0.08904 | Jul 2, 2024 |
| Mar 19, 2024 | $0.0664 | Mar 26, 2024 |
Performance
LABD had a total return of 7.03% in the past year, including dividends. Since the fund's inception, the average annual return has been -50.50%.
News
LABD: An Absolute Avoid
Shorting and inverse bets don't work over time on average, making inverse funds like Direxion Daily S&P Biotech Bear 3X Shares ETF a big avoid. The LABD ETF is a triple-leveraged inverse ETF that focu...
LABU And LABD: Another Attractive Double-Short Pairs Trade
Pairing Direxion Daily's S&P Biotech Bull 3X Shares ETF with their S&P Biotech Bear 3X Shares ETF produces a low volatility couple. Shorting both assets is attractive because leveraged assets erode ov...
LABD: 3X Leveraged Inverse Fund In Biotechnology Sector Is Best Avoided
Direxion Daily S&P Biotech Bear 3X Shares ETF failed to generate decent yield & price growth over the past 90 months. I don't foresee this fund generating positive growth in the near future, either. L...
May MDA Breakout Stocks/ETFs Week 20 - 2023: High-Frequency Gainers To Give You An Edge
Two new Breakout Stocks for Week 20 with better than 10% short-term upside, ETF updates, and two Dow 30 Picks. Average cumulative returns for 2023 are +68.3% YTD. The negative MG Signal continues, but...
Leveraged Biotech ETFs: Hold LABU, Sell LABD
SPDR® S&P Biotech ETF, the Biotechnology Select Industry Index ETF, has an extreme short interest of 51.16%. XBI is in an uptrend since May-June 2022. Direxion Daily S&P Biotech Bull 3X Shares ETF, th...
MDA Breakout Stocks/ETFs Week 13 - March 2023: High-Frequency Gainers To Give You An Edge
Two new Breakout Stocks for Week 13 with better than 10% short-term upside and a Dow 30 Pick. Average cumulative returns for 2023 are +47.4% YTD. The Momentum Gauges® continue negative in bear funds f...
MDA Breakout Stocks/ETFs Week 12 - March 2023: High-Frequency Gainers To Give You An Edge
Two new Breakout Stocks for Week 12 with better than 10% short-term upside with ETFs and a Dow 30 Pick. Average cumulative returns for 2023 are +37.3% YTD. The Momentum Gauges® continue negative in be...
MDA Breakout Stocks/ETFs Week 11 - March 2023: High-Frequency Gainers To Give You An Edge
Two new Breakout Stocks for Week 11 with better than 10% short-term upside and Dow 30 Picks. Average cumulative returns for 2023 are +37.6% YTD. The Momentum Gauges® continued negative with bear funds...
The Sell Rating Of LABD Is Reaffirmed
Since July 8 when I rated LABD a SELL, the underlying biotechnology index has moved very little up or down; LABD declined 25.22%. The biotechnology sector has done relatively well during the last four...
LABD: A Bad Bad Drift
Leveraged ETFs have a non-linear, unpredictable behavior. A drift dashboard with 22 of them.
Leveraged Biotech ETFs: Buy LABU, Sell LABD
Starting with September 2021, LABU had a record sequence of nine consecutive months with negative returns. During the biotech downtrend from September 2021 to April 2022, LABD has returned 207%.
LABD: 3X Leveraged Investments Not Suitable For Long Term
3X inverse derivative investments are extremely volatile and risky.
Biotech Innovations Remain At Forefront
The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively r...
Moving Beyond COVID In Biopharma
Just over one year after COVID-19 disrupted our lives, we are now getting to the point where multiple vaccine options are nearly ubiquitous for those in the United States. Per the CDC, as of April 12,...